CAMBRIDGE, Mass.--(BUSINESS WIRE)--Constellation Pharmaceuticals, Inc. today announced that it has appointed Edward E. Harlow, Jr., Ph.D. as the company’s Chief Scientific Officer. This appointment reflects the Company’s strong scientific heritage and its progress in building the leading biopharmaceutical effort focused on discovering and developing new drugs targeting epigenetic regulation of the human genome. Dr. Harlow will direct Constellation’s research and drug discovery efforts, initially focused on new treatments for cancer.
